Hypertension and progression of renal disease.
That systemic hypertension is involved in the progression of human renal disease is mostly suggested by the way anti-hypertensive treatment affects the course of the disease. Clinical evidence has been obtained from observational studies as well as from studies of dietary protein restriction. In addition, several trials have compared the effects of different antihypertensive agents. The angiotensin-converting-enzyme inhibitors have the best renoprotective effect when compared to conventional agents and calcium channel blockers. In most studies, ACE-inhibitors approximately halved the risk of progressive renal functional deterioration in patients with non-diabetic nephropathies; this protection was associated with a significant reduction in systemic blood pressure and proteinuria. Statistical analysis, however, also suggests a direct effect of ACE-inhibitors on the kidney.
Division of Nephrology, University Hospital, Verona, Italy.
G
G
Maschio
L
L
Oldrizzi
C
C
Marcantoni
C
C
Rugiu
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D018450:Disease Progression; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D007674:Kidney Diseases / Q000150:complications* / Q000503:physiopathology*
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents